Oncogenic Driver Mutant Analysis, Resistance Profiling, and Precision Reagents for Medullary Thyroid Cancer Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RET M918T drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Mutant Kinase | RET M918T Kinase Domain Protein High purity (>95%), Endotoxin <1EU/ug, Sequence Verified, Theoretical MW confirmed. Suitable for ATP competition assays. |
View RET M918T Products |
| Wild-Type Control | RET WT Kinase Domain Protein For selectivity screening and differential binding studies against wild-type RET. |
View RET Products |
| Gene Delivery | RET M918T Lentivirus Premade Particles Full-length mutant ORF for stable BaF3 or NIH3T3 cell line construction. Endotoxin controlled. |
View RET M918T Products |
| Detection Ab | Anti-RET Antibody (Recombinant Rabbit) For Western Blot, IP, and Flow Cytometry validation of RET expression. |
View RET Products |
| Validator | RET siRNA Set (3 unique sequences) For knockdown validation and specificity controls in cellular assays. |
View RET Products |
| Safety Counter-Screen | VEGFR2 (KDR) Kinase Domain Critical off-target liability for RET inhibitors; cardiovascular toxicity screening. |
View VEGFR2 Products |
| Resistance Pathway | ALK Bypass signaling analysis for acquired resistance mechanisms. |
View ALK Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| WT vs M918T Selectivity Screening | Matched pair of WT and M918T Kinase Domains, both >95% purity, Sequence Verified, produced in identical expression systems for consistent comparative studies. |
| Active Conformation Stability | High purity (>95%) minimizes aggregate interference; Theoretical MW confirmed by mass spectrometry; Endotoxin <1EU/ug ensures no LPS-induced signaling artifacts. |
| Cellular Context (M918T Signaling) | Lentivirus particles for stable, high-titer integration into BaF3 or NIH3T3 cells; preserves native phosphorylation patterns for autophosphorylation assays. |
| Comprehensive Resistance Panel | Additional RET gatekeeper mutants (V804M, V804L) and solvent front mutants available for combination resistance profiling. |
Live RET M918T R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for RET M918T is shifting from multi-kinase inhibitors to highly selective RET blockers. While first-generation agents like selpercatinib and pralsetinib show activity against M918T, the emergence of compound mutations and activation loop resistance necessitates next-generation inhibitors with improved binding geometry. The current R&D wave focuses on overcoming the constitutive activation conferred by the M918T mutation through allosteric inhibition or type II binding modes, alongside combination strategies targeting parallel angiogenic pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Type II RET Inhibitors | Turning Point, Novartis | MEN2B, Sporadic MTC | M918T vs WT Kinase Selectivity Panel (Need high-purity mutant proteins) |
| Next-gen Macrocycles | Various Biotech | RET+ Solid Tumors | Compound Mutation Assays (M918T + Gatekeeper) |
| Combination Therapy | Eli Lilly, Blueprint | Refractory MTC | VEGFR2 Off-target Screening (Need homolog panel) |
Molecular Differentiation & Assay Strategy
Key Differentiation Parameters
- Affinity & Binding Mode: M918T mutation induces an "open" activation loop conformation, reducing ATP affinity but increasing kinase activity. Optimal drugs require Type II binding (DFG-out conformation) rather than simple ATP competition. Assay need: Slow-off kinetics detection (e.g., SPR) beyond simple IC50.
- Selectivity Profile (Safety): VEGFR2 selectivity is a core differentiator. M918T inhibitors must maintain nanomolar potency against mutant RET while achieving >100-fold IC50 window over VEGFR2 to avoid hypertension and bleeding risks. Assay need: Parallel screening against VEGFR2, FLT3, KIT using standardized protein batches.
- Mutation Coverage Breadth: Inhibitors must retain activity against gatekeeper mutations (G810A, V804M) to address acquired resistance. Assay need: RET mutant panel (M918T single, M918T/V804M double) for parallel screening.
- Subcellular Localization & Stability: Constitutive activation accelerates receptor ubiquitination and degradation; drugs must stabilize kinase domain conformation. Assess aggregation propensity at high concentrations (>50 mg/mL). Assay need: Thermal shift assays (TSAs) and concentration-dependent dynamic light scattering (DLS).
TarMart Solution Technical Match
- Biochemical Grade Protein (RET M918T Kinase Domain): Sequence verified by NGS (ATG→ACG mutation), >95% purity to avoid chaperone interference, theoretical MW confirmed by mass spectrometry for consistent phosphorylation status.
- Cell Model Construction (RET M918T Lentivirus): Lentivirus preferred for stable BaF3-RET M918T cell lines preserving membrane topology and signaling pathways. Used for autophosphorylation (Y905, Y1015) and downstream ERK/AKT inhibition assays.
- Control System Integrity: Matched WT and M918T proteins from identical expression systems; VEGFR2 homolog protein as standard off-target control.
Related Target Recommendations (Cross-Selling)
- RET (Wild-Type): Required for selectivity index calculation in all M918T projects.
- VEGFR2 (KDR): Key off-target for cardiovascular toxicity screening; distinguishes pan-kinase inhibitors from selective RET drugs.
- ALK: Bypass signaling driver in MTC; potential second-line therapy for M918T inhibitor-resistant patients.
- RET V804M: Common compound resistance mutation with M918T; needed for broad-spectrum resistance testing.
Execution Recommendations
For RET M918T customer groups (primarily MTC drug development teams), TarMart should emphasize:
- "Resistance-Ready" Product Line: Highlight availability of M918T and V804M dual-mutant proteins, demonstrating foresight on resistance trends.
- Selectivity Data Package: Provide head-to-head RET M918T vs VEGFR2 assay protocols using high-purity homologous proteins.
- Cell Model Completeness: Emphasize lentivirus-constructed BaF3-RET M918T cell lines for IL-3 independent proliferation assays, the gold standard for assessing M918T gain-of-function.